Literature DB >> 1903543

Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse.

H Kaneshima1, C C Shih, R Namikawa, L Rabin, H Outzen, S G Machado, J M McCune.   

Abstract

The SCID-hu mouse is a small animal in which human hematolymphoid organs can be engrafted and maintained in vivo. In this study, parameters are described for reproducible infection of SCID-hu mice after i.v. inoculation. Infection was found to be dependent upon the time after inoculation, the virus isolate, the titer of virus, and the human target organ implanted into the mouse. Ten to 14 days after the i.v. administration of HIV isolates derived freshly from patients (e.g., JR-CSF, JR-FL, SM), 100% of engrafted human lymph nodes in SCID-hu mice were infected; greater than 95% of these animals were also viremic. Implants of human thymus or connective tissue, as well as the endogenous murine hematolymphoid organs, were not infected. As demonstrated by a combination of in situ hybridization and immunohistochemistry, both T-lymphoid and myelomonocytic lineage cells were infected in this system. HIV isolates that have been adapted to growth in vitro (e.g., HTLV-IIIb) were not infectious. When either 3'-azido-3'-deoxythymidine (AZT) or 2',3'-dideoxyinosine (ddIno) was administered to SCID-hu mice before HIV infection, the animals were protected in dose ranges similar to those used in man. This animal model may now be used as an efficient intermediate step between the lab and the clinic to study the infectious process in vivo and to best select efficacious antiviral compounds against HIV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903543      PMCID: PMC51693          DOI: 10.1073/pnas.88.10.4523

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.

Authors:  A Meyerhans; R Cheynier; J Albert; M Seth; S Kwok; J Sninsky; L Morfeldt-Månson; B Asjö; S Wain-Hobson
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

2.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

3.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.

Authors:  S Koenig; H E Gendelman; J M Orenstein; M C Dal Canto; G H Pezeshkpour; M Yungbluth; F Janotta; A Aksamit; M A Martin; A S Fauci
Journal:  Science       Date:  1986-09-05       Impact factor: 47.728

4.  SIV adaptation to human cells.

Authors:  V M Hirsch; P Edmondson; M Murphey-Corb; B Arbeille; P R Johnson; J I Mullins
Journal:  Nature       Date:  1989-10-19       Impact factor: 49.962

5.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

6.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization.

Authors:  M E Harper; L M Marselle; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

7.  In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.

Authors:  R Yarchoan; H Mitsuya; R V Thomas; J M Pluda; N R Hartman; C F Perno; K S Marczyk; J P Allain; D G Johns; S Broder
Journal:  Science       Date:  1989-07-28       Impact factor: 47.728

8.  Efficient isolation of HIV from plasma during different stages of HIV infection.

Authors:  A Ehrnst; A Sönnerborg; S Bergdahl; O Strannegård
Journal:  J Med Virol       Date:  1988-09       Impact factor: 2.327

9.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

10.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

View more
  18 in total

Review 1.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

2.  MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.

Authors:  C G Bridges; D L Taylor; P S Ahmed; T M Brennan; J M Hornsperger; J F Navé; P Casara; A S Tyms
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo.

Authors:  P S Koka; J K Fraser; Y Bryson; G C Bristol; G M Aldrovandi; E S Daar; J A Zack
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 4.  Studies of retroviral infection in humanized mice.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Virology       Date:  2015-02-11       Impact factor: 3.616

5.  Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse.

Authors:  H Kaneshima; L Su; M L Bonyhadi; R I Connor; D D Ho; J M McCune
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity.

Authors:  B D Jamieson; G M Aldrovandi; V Planelles; J B Jowett; L Gao; L M Bloch; I S Chen; J A Zack
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.

Authors:  L Rabin; M Hincenbergs; M B Moreno; S Warren; V Linquist; R Datema; B Charpiot; J Seifert; H Kaneshima; J M McCune
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice.

Authors:  D L Greiner; L D Shultz; J Yates; M C Appel; G Perdrizet; R M Hesselton; I Schweitzer; W G Beamer; K L Shultz; S C Pelsue
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

Review 9.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 10.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.